# O-GIcNAc as a strategy for the treatment of tauopathies

https://neurodegenerationresearch.eu/survey/o-glcnac-as-a-strategy-for-the-treatment-of-tauopathies/ Principal Investigators

**Gideon Davies** 

Institution

University of York

# Contact information of lead PI Country

United Kingdom

## Title of project or programme

O-GlcNAc as a strategy for the treatment of tauopathies

## Source of funding information

Alzheimer's Research UK

#### Total sum awarded (Euro)

€ 117,580

Start date of award

01/10/2012

Total duration of award in years

3.5

Keywords Research Abstract The class of neurodegenerative diseases collectively termed the tauopathies result from the aggregation of a toxic form of tau in with it is hyper(over) phosphorylated. Less well known is that tau phosphorylation is reciprocal to its modification with a sugar termed "O-GlcNAc" and that O-GlcNAc levels are, concomitantly, reduced in the diseased brain. Proof of concept studies show that the toxic form of tau can be significantly reduced using a small molecule strategy that therapeutically raises tau-O-GlcNAc levels. We aim to study, in detail, the human enzymes responsible for this effect, providing a platform on which to design the next generation of inhibitors providing a new approach to the treatment of tauopathies such as frontotemporal dementia.

#### Further information available at:

**Types:** Investments < €500k

Member States: United Kingdom

**Diseases:** N/A

**Years:** 2016

Database Categories: N/A

**Database Tags:** N/A